Asthma pathophysiology and evidence-based treatment of severe exacerbations

American Journal of Health-System Pharmacy

Volumn 63, Issue SUPPL. 3, 2006, Pages

  Schreck, David M ^a  

^a Summit Medical Group ^*  (United States)

Author keywords

Albuterol; Asthma; Costs; Drug comparisons; Economics; Levalbuterol; Mechanism of action; Steroids, cortico ; Sympathomimetic agents; Toxicity

Indexed keywords

ADRENALIN; AMINOPHYLLINE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DESLORATADINE; FENOTEROL; FEXOFENADINE; GUAIFENESIN; HELIOX; HYDROCORTISONE; IPRATROPIUM BROMIDE; LEUKOTRIENE DERIVATIVE; LEVALBUTEROL; LORATADINE; MAGNESIUM SULFATE; METHYLXANTHINE DERIVATIVE; MUCOLYTIC AGENT; OMALIZUMAB; ORCIPRENALINE; OXYGEN; PIRBUTEROL; SALBUTAMOL; TERBUTALINE; THEOPHYLLINE; UNINDEXED DRUG;

ARTICLE; ASTHMA; BRONCHODILATATION; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENANTIOMER; EVIDENCE BASED MEDICINE; FLUSHING; FORCED EXPIRATORY VOLUME; HEADACHE; HEALTH CARE COST; HEMATEMESIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; LUNG FUNCTION; MORBIDITY; NAUSEA; NEBULIZATION; NERVOUSNESS; OUTCOMES RESEARCH; OXYGEN THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RACEMIC MIXTURE; SEIZURE; SHOCK; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SWEATING; SYSTEMATIC REVIEW; TACHYCARDIA; TREMOR; VISUAL DISORDER; VOMITING; XEROSTOMIA;

EID: 33646802222     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060127     Document Type: Article

References (40)

1. National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma: Expert Panel Report 2. Washington, DC: U.S. Department of Health and Human Services; 1997. NIH publication no. 97-4051.
2. Meltzer EO. The role of the immune system in the pathogenesis of asthma and an overview of the diagnosis, classification, and current approach to treating the disease. J Manag Care Pharm. 2003; 9(5 suppl):8-13.
3. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med. 2001; 164(10 pt 2):S28-38.
4. National Heart, Lung, and Blood Institute. Executive summary of the NAEPP expert panel report: guidelines for the diagnosis and management of asthma-update on selected topics 2002. NIH publication no. 02-5075. http://www. nhlbi.nih.gov/guidelines/asthma/asthsumm.htm (accessed 2006 March 31).
5. D'Alonzo GE. Theophylline revisited Allergy Asthma Proc. 1996; 17:335-9.
6. Rossing TH, Fanta CH, Goldstein DH et al. Emergency therapy of asthma: comparison of the acute effects of parenteral and inhaled sympathomimetics and infused aminophylline. Am Rev Respir Dis. 1980; 122:365-71.
7. Rodrigo C, Rodrigo G. Treatment of acute asthma. Lack of therapeutic benefit and increase of the toxicity from amino-phylline given in addition to high doses of salbutamol delivered by metered-dose inhaler with a spacer. Chest. 1994; 106:1071-6.
8. Higgins JC. The 'crashing asthmatic.' Am Fam Physician. 2003; 67:997-1004.
9. McEvoy GK, ed. Magnesium sulfate. In: AHFS Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists; 2005:2155-9.
10. Skobeloff EM, Spivey WH, McNamara RM et al. Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA. 1989; 262:1210-3.
11. Bloch H, Silverman R, Mancherje N et al. Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest. 1995; 107:1576-81.
12. Silverman RA, Osborn H, Runge J et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest. 2002; 122:489-97.
13. Gluck EH, Onorato DJ, Castriotta R. Helium-oxygen mixtures in intubated patients with status asthmaticus and respiratory acidosis. Chest. 1990; 98:693-8.
14. Manthous CA, Hall JB, Caputo MA et al. Heliox improves pulsus paradoxus and peak expiratory flow in nonintubated patients with severe asthma. Am J Respir Crit Care Med. 1995; 151(2 pt 1):310-4.
15. McEvoy GK, ed. Ipratropium bromide. In: AHFS Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists; 2005:1246-52.
16. Bryant DH. Nebulized ipratropium bromide in the treatment of acute asthma. Chest. 1985; 88:24-9.
17. Ward MJ, Macfarlane JT, Davies D. A place for ipratropium bromide in the treatment of severe acute asthma. Br J Dis Chest. 1985; 79:374-8.
18. Schreck DM, Tricarico VJ, Figueroa D et al. Comparison of ipratropium bromide vs. placebo in the emergency management of acute asthma. Acad Emerg Med. 1997 (May).
19. Karpel JP, Schacter EN, Fanta C et al. A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma. Chest. 1996; 110:611-6.
20. FitzGerald JM, Grunfeld A, Pare PD et al. The clinical efficacy of combination nebulized anticholinergic and adrenergic bronchodilators vs nebulized adrenergic bronchodilator alone in acute asthma. Canadian Combivent Study Group. Chest. 1997; 111:311-5.
21. Rodrigo GJ, Castro-Rodriguez JA. Anti-cholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax. 2005; 60:740-6.
22. Rodrigo G, Rodrigo C, Burschtin O. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Am J Med. 1999; 107:363-70.
23. FDA Public Health Advisory: Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder). November 18, 2005. http://www.fda.gov/cder/drug/advisory/LABA.htm (accessed 2006 Jan 31).
24. Lanes SF, Garcia Rodriguez LA, Huerta C. Respiratory medications and risk of asthma death. Thorax. 2002; 57:683-6.
25. Spitzer WO, Suissa S, Ernst P et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992; 326:501-6.
26. McEvoy GK, ed. Epinephrine hydrochloride. In: AHFS Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists; 2005:2736-7.
27. McEvoy GK, ed. Albuterol, albuterol sulfate, and levalbuterol hydrochloride. In: AHFS Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists; 2005:1259-70.
28. McEvoy GK, ed. Isoproterenol hydrochloride. In: AHFS Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists; 2005:1289-92.
29. McEvoy GK, ed. Terbutaline sulfate. In: AHFS Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists; 2005:1317-21.
30. Mitra S, Ugur M, Ugur O et al. (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol. 1998; 53:347-54.
31. Perrin-Fayolle M. Salbutamol in the treatment of asthma. Lancet. 1995; 346:1101.
32. Gumbhir-Shah K, Kellerman DJ, DeGraw S et al. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. J Clin Pharmacol. 1998; 38:1096-106.
33. Mazzoni L, Naef R, Chapman ID et al. Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta 2-selective sympathomimetics. Pulm Pharmacol. 1994; 7:367-76.
34. Nelson HS, Bensch G, Pleskow WW et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol. 1998; 102(6 pt 1):943-52.
35. Nowak RM, Emerman CL, Schaefer K et al. Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. Am J Emerg Med. 2004; 22:29-36.
36. Xopenex inhalation solution package insert. Marlborough, MA: Sepracor Inc.; May 2004.
37. Haider D. Levalbuterol affords superior health and cost benefit over racemic albuterol in the emergency department. Respir Care. 2001; 46:1081. Abstract.
38. Carl JC, Myers TR, Kirchner HL et al. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr. 2003; 143:731-6.
39. Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med. 2005; 23:842-7.
40. Asmus MJ, Hendeles L. Levalbuterol nebulizer solution: is it worth five times the cost of albuterol? Pharmacotherapy. 2000; 20:123-9.